Genmab Shares Surge Following Positive Phase 3 Trial Results for Petosemtamab
Genmab (GMAB) shares rose approximately 15% following the announcement of positive Phase 3 clinical trial data. The results demonstrated that its bispecific antibody therapy, petosemtamab, used in combination with Merck's (MRK) Keytruda, reduced mortality risk by 50% in specific patient groups suffering from head and neck cancer. The successful trial outcome highlights the potential of Genmab's oncology pipeline and reinforces its strategic partnership with Merck. This development is expected to strengthen the market position of both companies within the immunotherapy sector as they move toward potential regulatory milestones.
Topics: clinical trial results drug efficacy oncology stock price movement
Read the full article at Seeking Alpha
Part of the story Merck's sacituzumab tirumotecan Reduces Death Risk by 32% in Endometrial Cancer Phase 3 Trial (2 articles)